The Hypo-RESOVLE consortium is very pleased to announce that the IMI approved an 18 months’ no-cost extension of the Hypo-RESOLVE action end of April 2022. The project will now terminate in October 2023. The consortium greeted this decision with enthusiasm since it will allow them to compensate for the severe COVID-related delays, which particularly hit the activities depending on patient recruitment and animal research. The Hypo-RESOLVE partners will now have the opportunity to complete their work towards the action’s objectives and accomplish the results the consortium set out to achieve.